Cargando…

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

BACKGROUND: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bogani, Costanza, Bartalucci, Niccolò, Martinelli, Serena, Tozzi, Lorenzo, Guglielmelli, Paola, Bosi, Alberto, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561413/ https://www.ncbi.nlm.nih.gov/pubmed/23382981 http://dx.doi.org/10.1371/journal.pone.0054826

Ejemplares similares

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
por: Bartalucci, Niccolò, et al.
Publicado: (2013)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
por: Bartalucci, Niccolò, et al.
Publicado: (2017)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway
por: Čokić, Vladan P., et al.
Publicado: (2015)

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
por: Choong, Meng Ling, et al.
Publicado: (2013)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms
por: Huang, Shih-Min A., et al.
Publicado: (2014)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
por: Deshpande, Anagha, et al.
Publicado: (2011)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
por: Zhao, Ailin, et al.
Publicado: (2023)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
por: Tapper, William, et al.
Publicado: (2015)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
por: Nakaya, Y, et al.
Publicado: (2011)

P1004: EFFECT AND MOLECULAR MECHANISM OF TQ05105, A NOVEL SMALL MOLECULE INHIBITOR OF JAK2 IN MYELOPROLIFERATIVE NEOPLASM
por: Zhang, W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fdtl2boipv2re636udrdq6c1b3